<DOC>
	<DOCNO>NCT01166958</DOCNO>
	<brief_summary>Current osteoporosis therapy produce prompt increase bone mass , follow modest subsequent gain . This limitation , know `` remodel transient , '' reflect `` couple '' bone resorption formation intervention impact either process lead compensatory change . For example , medication increase bone formation promptly also stimulate bone resorption . Thus , give need dramatically increase bone mass patient osteoporosis , necessary `` uncouple '' formation resorption . The investigator believe possible use currently exist FDA-approved therapeutic agent , use novel , sequential approach . This pilot project obtain preliminary data essential support future work . In study , investigator begin explore use sequential anabolic treatment teriparatide follow antiresorptive therapy raloxifene . The investigator propose sequential treatment allow open `` anabolic window , '' brief period time follow initiation teriparatide therapy bone formation exceed resorption .</brief_summary>
	<brief_title>Enhancing Osteoporosis Therapy : Can We Open Anabolic Window ?</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Generally healthy , communitydwelling ambulatory postmenopausal woman . Able willing sign inform consent . Age 60 89 . Have osteoporosis define follow : BMD Tscore lumbar spine , femur neck , total proximal femur .3 radius 2.5 4.0 ; note : lumbar spine must include two vertebra evaluable DXA opinion investigator . OR BMD Tscore lumbar spine , femur neck , total proximal femur .3 radius 1.5 low either atraumatic ( opinion investigator ) nonvertebral fracture ; [ note : nonvertebral fracture site include wrist , hip , pelvis , rib , humerus , clavicle , femur , tibia fibula ] minimum two mild one moderate severe atraumatic vertebral fracture ( define use Genant visual semiquantitative scale ) . Baseline serum 25 ( OH ) D concentration &gt; 20 ng/ml &lt; 60 ng/ml . Able willing receive daily subcutaneous injection use Forteo® pen . History exposure external beam implant radiation therapy involve skeleton . Paget 's disease unexplained elevation alkaline phosphatase . Any history venous thrombosis include deep vein thrombosis , pulmonary embolism , retinal vein thrombosis superficial phlebitis . Documented atherosclerotic vascular disease , include limited prior myocardial infarction , angina , atrial fibrillation , stroke TIA . Marked hypertriglyceridemia ( &gt; 500 mg/dl ) . History prior treatment estrogen result hypertriglyceridemia ( &gt; 500 mg/dl ) . Serum calcium , alkaline phosphatase , PTH TSH outside normal reference range . History nephrolithiasis urolithiasis within 10 year prior enrollment ; history nephro urolithiasis must appropriate radiology study ( e.g. , IVP KUB ) within six month document absence stone . Baseline 24hour urine calcium &gt; 250 mg . Known risk factor hypercalcemia , e.g. , malignancy , tuberculosis , sarcoidosis . History form cancer except adequately treat squamous cell basal cell skin carcinoma . Use active vitamin D analogs high dose vitamin D ( ≥50,000 IU weekly ) last year . Active suspect disease ( within 1 year prior enrollment ) affect bone metabolism , e.g. , renal osteodystrophy , hyperthyroidism , osteomalacia , hyperparathyroidism . Known allergy , hypersensitivity , contraindication intolerance teriparatide raloxifene . History vaginal bleeding within past year . Renal failure substantial hepatic impairment . Note `` renal failure '' define calculate creatinine clearance ( use CockroftGault formula ) ≤ 35 ml/minute . Severe disease , e.g. , cardiac , hepatic , pulmonary , etc. , may limit ability complete study . Specifically , significantly impair hepatic function ( ALT GGT 3x upper limit normal . Known malabsorption syndrome , e.g. , celiac disease , active inflammatory bowel disease , gastric bypass , etc . Use anion exchange resin ( e.g. , cholestyramine ) past month . Current use warfarin ( coumadin ) . Current use highly proteinbound drug include diazepam , diazoxide lidocaine . Current use digoxin . Any prior use bisphosphonates , denosumab , strontium , fluoride , teriparatide parathyroid hormone . Prior use estrogen , raloxifene , calcitonin testosterone allow discontinue six month previously . Low dose intravaginal estrogen ( 0.3 mg less conjugated equine estrogen equivalent ) may continue throughout study . Treatment glucocorticoids dos ≥ 5 mg prednisone daily &gt; 30 day prior year . Treatment drug know affect bone metabolism , e.g. , anticonvulsant except benzodiazepine gabapentin , within prior year . Note : oral calcium supplementation , vitamin D supplementation diuretic use stable six month allow ) . Treatment within last 30 day drug receive regulatory approval . Metal spine preclude spine QCT . Any condition may interfere evaluation least two lumbar vertebra determine VFA perform time screening . Examples include confluent aortic calcification , severe osteoarthritis , spinal fusion lumbar spine fracture .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>